Back to Search
Start Over
Clinical efficacy and changes of serum VEGF-A, VEGF-B, and PLGF after conbercept treating neovascular age-related macular degeneration
- Source :
- International Journal of Ophthalmology, Vol 16, Iss 9, Pp 1489-1495 (2023)
- Publication Year :
- 2023
- Publisher :
- Press of International Journal of Ophthalmology (IJO PRESS), 2023.
-
Abstract
- AIM: To evaluate the clinical efficacy and systemic safety profile of conbercept in clinical practice on vascular endothelial growth factor (VEGF)-A, VEGF-B, and placental growth factor (PLGF) levels after intravitreal injections for the neovascular age-related macular degeneration (AMD). METHODS: Thirty-five patients (35 eyes) with neovascular AMD received intravitreal injections of conbercept treatment with pro re nata protocol. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were detected before the intravitreal injection and at 1, 3, and 12mo after conbercept treatment. The levels of serum VEGF-A, VEGF-B, and PLGF were measured by enzyme-linked immunosorbent assay before the injection and 1 and 12mo after conbercept treatments. RESULTS: At baseline, the mean BCVA score was 39.89±14.64 letters. The mean BCVA scores were 51.03±15.78, 56.71±14.38, and 52.49±10.16 letters at 1, 3, and 12mo after conbercept treatment, and the BCVA improvements were all significant, respectively (P0.05). CONCLUSION: Conbercept intravitreal injection leads to BCVA and CRT improvement, however, it does not significantly affect systemic serum VEGF-A, VEGF-B, and PLGF levels at 1 and 12mo after intravitreal injection treating neovascular AMD.
Details
- Language :
- English
- ISSN :
- 22223959 and 22274898
- Volume :
- 16
- Issue :
- 9
- Database :
- Directory of Open Access Journals
- Journal :
- International Journal of Ophthalmology
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.8063db25f93d4084bca3b94f6665b622
- Document Type :
- article
- Full Text :
- https://doi.org/10.18240/ijo.2023.09.16